

## AUBAGIO (teriflunomide) [preferred] PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Aubagio are located in the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapters – **Multiple Sclerosis Agents** and **Quantity Limits/Daily Dose Limits** accessible at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

<b>Medication requested:</b> Aubagio tablet	Strength:	Quantity:	Refills:
Directions:			
Diagnosis ( <i>submit documentation</i> ):			Dx code ( <i>required</i> ):
1. Which specialty pharmacy will be used?	<input type="checkbox"/> Diplomat Specialty Pharmacy	<input type="checkbox"/> Walgreen's Specialty Pharmacy	
2. Does the beneficiary have a diagnosis of a relapsing form of multiple sclerosis?	<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis.</i> <input type="checkbox"/> No – <i>Submit documentation supporting the use of Aubagio for the beneficiary's diagnosis.</i>		
3. Is the requested medication prescribed by a neurologist?	<input type="checkbox"/> Yes <input type="checkbox"/> No – specialty: _____		
4. Does the beneficiary have evidence of active infection?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
5. Does the beneficiary have severe hepatic impairment?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
6. Is the beneficiary currently taking leflunomide (Arava)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
7. Does the beneficiary have a diagnosis of severe immunodeficiency or bone marrow disease?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
8. Does the beneficiary have documentation of blood pressure monitoring, including baseline and follow-up measurements?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
9. <b><i>For females of childbearing potential</i></b> , does the beneficiary have documentation of a recent negative pregnancy test?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		

#### Initial requests

1. Does the beneficiary have results of the following? *Check all that apply and submit documentation for each.*
- |  |  |
|--|--|
| <input type="checkbox"/> recent negative PPD or blood test for tuberculosis              | <input type="checkbox"/> transaminase and bilirubin levels with ALT ≤ 2x the upper limit of normal within 6 months prior to starting Aubagio |
| <input type="checkbox"/> CBC with differential within 6 months prior to starting Aubagio |  |

#### Renewal requests

- |  |   |
|--|---|
| 1. Has the beneficiary experienced improvement or stabilization of the signs and symptoms of multiple sclerosis since starting Aubagio?                                      | <input type="checkbox"/> Yes <i>Submit documentation of beneficiary's response to therapy.</i><br><input type="checkbox"/> No |
| 2. Does the beneficiary have results of liver function tests (LFTs) monitored monthly for the first 6 months after starting Aubagio with ALT ≤ 3x the upper limit of normal? | <input type="checkbox"/> Yes <i>Submit documentation of lab results.</i><br><input type="checkbox"/> No                       |

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.